Back to Archived News
Cohera Medical, Inc. Awarded Patent, Second SBIR Grant
Thursday, August 02, 2007
Pittsburgh, PA -- Cohera Medical, Inc., a rapidly growing medical device company developing a suite of novel surgical adhesives, announced today that it has been awarded a U.S. patent on its innovative surgical adhesive. The technology, developed at the University of Pittsburgh by Drs. Eric Beckman and Michael Buckley, provides a platform for strong, resorbable adhesives for use inside the body.
Cohera's first product, TissuGlu™, is currently in pre-clinical testing and is designed to adhere tissues to prevent fluid accumulation in deep wounds. Cohera has also won a Phase 1 SBIR Award for the design and development of a bioresorbable bone adhesive for orthopedic use. This award, for ~$130,000, is the company's second SBIR award this year. Dr. Eric Beckman, Chief Scientific Officer and Co-Founder of Cohera Medical, will serve as the Principal Investigator on the study.
"The grant of Cohera's first patent reinforces the novelty of our core technology platform, and adds significant value to the company. The SBIR award further reinforces the breadth and potential for a variety of products that meet surgeons' needs across many specialties," said Patrick Daly, President and CEO of Cohera Medical.
In addition to the patent and funding secured by the SBIR Award, Cohera Medical also announced today it has secured the talents of a key regulatory affairs professional with deep roots in the medical device sector.
Kay Fuller will join the company from Ann Arbor, MI as the Director of Clinical and Regulatory Affairs effective immediately.
"Ms. Fuller is a highly creative and strategic regulatory affairs professional who will lead the global regulatory strategy for Cohera Medical, Inc.," said Mr. Daly. "With more than twenty years of domestic and international regulatory and clinical experience in the medical device industry, Ms. Fuller has an extensive and successful background developing Class II and Class III implantable medical devices such as brain shunts, left ventricular assist devices, vena cava filters, and vascular grafts."
Ms. Fuller worked closely with the Food and Drug Administration on many pre-market submissions for leading medical device companies, including W.L. Gore & Associates, PS Medical, CR Bard and Terumo Corporation. Ms. Fuller has been instrumental in gaining FDA approvals and clearances to market more than 25 medical devices via the 510k, IDE and PMA submission process.
"Kay brings a great deal of medical device experience to Cohera and will be an integral part of our success and ability to drive shareholder value," said Dr. Dottie Clower, Vice President of Business Development and Operations at Cohera. "Her passion, energy and expertise in the regulatory and clinical space make her well suited to lead our global regulatory strategy."
About Cohera Medical, Inc.
Cohera Medical, Inc. is a Pittsburgh-based medical device company that is developing a suite of biodegradable surgical adhesives. Cohera's first product, TissuGlu™, currently in pre-clinical testing, is an easy-to use, strong and resorbable polymer adhesive aimed at fulfilling the market demand for a strong, safe tissue adhesive that will improve the wound closure process by positioning tissues for optimal healing while minimizing fluid accumulation. The flexibility of Cohera's proprietary chemistry supports a family of products with differences in strength, set time and resorption rate that Cohera believes will meet the varying specific demands and requirements of the market. Cohera Medical, Inc.
Back to Archived News
